Legal Insights

< back to search results

2018 outlook for drugs and medical devices in China: regulatory reform fueled by innovation

Overview

The year 2017 ended with a central government directive to reform the regulatory approval system for drugs and medical devices and a subsequent flood of CFDA changes and proposed changes to the system.


This article explores possible further regulatory reform in 2018 as the Chinese government continues to encourage domestic innovation in this sector.

Categories related to China